(RTTNews) - Drug maker GSK plc (GSK, GSK.L) announced Tuesday that Blenrep (belantamab mafodotin) combinations in relapsed/refractory multiple myeloma have been accepted for regulatory review in ...

China’s National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) has granted breakthrough therapy designation (BTD) for GSK's Blenrep (belantamab mafodotin ...

GSK is betting that Blenrep--a blood-cancer treatment that U.S. drug regulators asked it to pull from the market in 2022--could get a second chance, part of a push by the British pharma giant to ...

(Alliance News) - GSK PLC on Tuesday said its Blenrep cancer treatment will undergo review in Japan after successful authorisations recently in the UK and Europe. The London-based pharmaceutical ...

GSK plc announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China has granted Breakthrough Therapy Designation (BTD) for Blenrep (belantamab ...

of the National Medical Products Administration or NMPA in China has granted Breakthrough Therapy Designation to Blenrep (belantamab mafodotin) in combination with bortezomib and dexamethasone or ...

GSK plc announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has accepted for review a new drug application (NDA) for Blenrep (belantamab mafodotin) in combination with bortezomib plus ...

The FDA has approved GlaxoSmithKline’s multiple myeloma drug Blenrep, a first-in-class potential blockbuster that will be used in advanced disease. Blenrep (belantamab mafodotin) has been ...

(Alliance News) - GSK PLC on Friday announced that it has been granted breakthrough therapy designation in China for Blenrep, a treatment for relapsed or refractory multiple myeloma. The London ...

A year after GSK pulled its BCMA-targeting antibody-drug conjugate (ADC) Blenrep from the US market as a later-line therapy for multiple myeloma, there are signs that the drug may still have a ...

Berenberg estimates an around 9% return on R&D investment from its current late-stage pipeline dominated by its multiple myeloma treatment Blenrep and its severe asthma drug depemokimab ...